Anti-tumor gene therapy

C. Cirielli, M. C. Capogrossi, A. Passaniti

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Gene therapy as an anti-tumor strategy is becoming a powerful tool for cytokine delivery to inhibit the growth of many tumors. Several delivery systems are being utilized and designed for the expression of specific genes to achieve a therapeutic result. Liposomes, retroviral vectors, and adenoviral vectors have all been used and eventual clinical application may depend on the type of tumor, the location, the specific gene carried, and the patient's health status. Novel expression vectors may eventually achieve tissue-specific targeting and low immuno-reactivity. Inactivation of mutated oncogenes, such as ras, or re-expression of inactive suppressor genes, such as p53 have been used as strategies for anti-tumor therapy. Additionally, exogenous genes, such as viral thymidine kinase that metabolize chemotherapeutic agents to achieve local cytotoxicity have also been employed. Neuro-endocrine tumors are targets of these genetic strategies since they are often difficult to treat by conventional methods because of their location (brain tumors) or because they have spread from the primary tumor (melanoma). Further advances in the design of these vectors may achieve safe targeting of a variety of malignant tumors.

Original languageEnglish
Pages (from-to)217-223
Number of pages7
JournalJournal of Neuro-Oncology
Volume31
Issue number1-2
Publication statusPublished - 1997

Fingerprint

Genetic Therapy
Neoplasms
Suppressor Genes
Thymidine Kinase
Oncogenes
Brain Neoplasms
Liposomes
Genes
Health Status
Melanoma
Cytokines
Gene Expression
Therapeutics
Growth

Keywords

  • Adenovirus
  • Gene therapy
  • Liposome
  • Retrovirus

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Cirielli, C., Capogrossi, M. C., & Passaniti, A. (1997). Anti-tumor gene therapy. Journal of Neuro-Oncology, 31(1-2), 217-223.

Anti-tumor gene therapy. / Cirielli, C.; Capogrossi, M. C.; Passaniti, A.

In: Journal of Neuro-Oncology, Vol. 31, No. 1-2, 1997, p. 217-223.

Research output: Contribution to journalArticle

Cirielli, C, Capogrossi, MC & Passaniti, A 1997, 'Anti-tumor gene therapy', Journal of Neuro-Oncology, vol. 31, no. 1-2, pp. 217-223.
Cirielli C, Capogrossi MC, Passaniti A. Anti-tumor gene therapy. Journal of Neuro-Oncology. 1997;31(1-2):217-223.
Cirielli, C. ; Capogrossi, M. C. ; Passaniti, A. / Anti-tumor gene therapy. In: Journal of Neuro-Oncology. 1997 ; Vol. 31, No. 1-2. pp. 217-223.
@article{7886c105c85d4404896e4830a6b124c0,
title = "Anti-tumor gene therapy",
abstract = "Gene therapy as an anti-tumor strategy is becoming a powerful tool for cytokine delivery to inhibit the growth of many tumors. Several delivery systems are being utilized and designed for the expression of specific genes to achieve a therapeutic result. Liposomes, retroviral vectors, and adenoviral vectors have all been used and eventual clinical application may depend on the type of tumor, the location, the specific gene carried, and the patient's health status. Novel expression vectors may eventually achieve tissue-specific targeting and low immuno-reactivity. Inactivation of mutated oncogenes, such as ras, or re-expression of inactive suppressor genes, such as p53 have been used as strategies for anti-tumor therapy. Additionally, exogenous genes, such as viral thymidine kinase that metabolize chemotherapeutic agents to achieve local cytotoxicity have also been employed. Neuro-endocrine tumors are targets of these genetic strategies since they are often difficult to treat by conventional methods because of their location (brain tumors) or because they have spread from the primary tumor (melanoma). Further advances in the design of these vectors may achieve safe targeting of a variety of malignant tumors.",
keywords = "Adenovirus, Gene therapy, Liposome, Retrovirus",
author = "C. Cirielli and Capogrossi, {M. C.} and A. Passaniti",
year = "1997",
language = "English",
volume = "31",
pages = "217--223",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Springer New York LLC",
number = "1-2",

}

TY - JOUR

T1 - Anti-tumor gene therapy

AU - Cirielli, C.

AU - Capogrossi, M. C.

AU - Passaniti, A.

PY - 1997

Y1 - 1997

N2 - Gene therapy as an anti-tumor strategy is becoming a powerful tool for cytokine delivery to inhibit the growth of many tumors. Several delivery systems are being utilized and designed for the expression of specific genes to achieve a therapeutic result. Liposomes, retroviral vectors, and adenoviral vectors have all been used and eventual clinical application may depend on the type of tumor, the location, the specific gene carried, and the patient's health status. Novel expression vectors may eventually achieve tissue-specific targeting and low immuno-reactivity. Inactivation of mutated oncogenes, such as ras, or re-expression of inactive suppressor genes, such as p53 have been used as strategies for anti-tumor therapy. Additionally, exogenous genes, such as viral thymidine kinase that metabolize chemotherapeutic agents to achieve local cytotoxicity have also been employed. Neuro-endocrine tumors are targets of these genetic strategies since they are often difficult to treat by conventional methods because of their location (brain tumors) or because they have spread from the primary tumor (melanoma). Further advances in the design of these vectors may achieve safe targeting of a variety of malignant tumors.

AB - Gene therapy as an anti-tumor strategy is becoming a powerful tool for cytokine delivery to inhibit the growth of many tumors. Several delivery systems are being utilized and designed for the expression of specific genes to achieve a therapeutic result. Liposomes, retroviral vectors, and adenoviral vectors have all been used and eventual clinical application may depend on the type of tumor, the location, the specific gene carried, and the patient's health status. Novel expression vectors may eventually achieve tissue-specific targeting and low immuno-reactivity. Inactivation of mutated oncogenes, such as ras, or re-expression of inactive suppressor genes, such as p53 have been used as strategies for anti-tumor therapy. Additionally, exogenous genes, such as viral thymidine kinase that metabolize chemotherapeutic agents to achieve local cytotoxicity have also been employed. Neuro-endocrine tumors are targets of these genetic strategies since they are often difficult to treat by conventional methods because of their location (brain tumors) or because they have spread from the primary tumor (melanoma). Further advances in the design of these vectors may achieve safe targeting of a variety of malignant tumors.

KW - Adenovirus

KW - Gene therapy

KW - Liposome

KW - Retrovirus

UR - http://www.scopus.com/inward/record.url?scp=0031058429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031058429&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 217

EP - 223

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1-2

ER -